Pfizer (PFE) Cost of Revenue (2009 - 2026)

Pfizer has disclosed Cost of Revenue across 18 years of filings, most recently posting $3.5 billion for Q1 2026.

• In Q1 2026, Cost of Revenue rose 24.71% year-over-year to $3.5 billion; the TTM figure through Mar 2026 stood at $16.8 billion (up 13.41% YoY), while the FY2025 annual figure was $16.1 billion, down 9.99% from the prior year.
• Cost of Revenue declined to $3.5 billion in Q1 2026, from $5.3 billion in the prior quarter.
• Over the last five years, Cost of Revenue for PFE reached as high as $10.0 billion in Q2 2022 and fell as low as $2.8 billion in Q1 2025.
• The 5-year median for Cost of Revenue is $4.9 billion (2023), against an average of $5.4 billion.
• Annual changes were most pronounced in 2022 — Cost of Revenue jumped 140.17% — and 2023, when it tumbled 62.57%.
• A 5-year view of Cost of Revenue shows it stood at $6.1 billion in 2022, then grew by 24.74% to $7.6 billion in 2023, then tumbled by 30.41% to $5.3 billion in 2024, then advanced by 0.17% to $5.3 billion in 2025, then slumped by 32.7% to $3.5 billion in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $3.5 billion, $5.3 billion, and $4.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.